In the last few years, a great interest has emerged in investigating the pleiotropic effects of
Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower …

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

Diabetes is associated with a two to three-fold increase in risk of cardiovascular disease.
However, intensive glucose-lowering therapy aiming at reducing HbA1c to a near-normal …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …

A growing body of evidence is emerging to show that abdominal obesity, the metabolic
syndrome, type 2 diabetes, cardiovascular disease and microvascular diabetic …

While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart
rate (HR), it is insufficiently recognized that the extent varies greatly between the various …

Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, with as
many as 415 million patients worldwide. T2DM is characterized by elevated blood glucose …

Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …